News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
574,847 Results
Type
Article (39356)
Company Profile (85)
Press Release (535406)
Multimedia
Podcasts (85)
Webinars (11)
Section
Business (174654)
Career Advice (2180)
Deals (28740)
Drug Delivery (90)
Drug Development (61946)
Employer Resources (147)
FDA (13950)
Job Trends (12622)
News (285688)
Policy (27126)
Tag
Academia (2198)
Academic (1)
Accelerated approval (5)
Adcomms (16)
Allergies (73)
Alliances (45048)
ALS (82)
Alzheimer's disease (1179)
Antibody-drug conjugate (ADC) (104)
Approvals (13965)
Artificial intelligence (254)
Autoimmune disease (18)
Automation (16)
Bankruptcy (267)
Best Places to Work (9938)
BIOSECURE Act (14)
Biosimilars (82)
Biotechnology (63)
Bladder cancer (66)
Brain cancer (21)
Breast cancer (251)
Cancer (1947)
Cardiovascular disease (153)
Career advice (1843)
Career pathing (27)
CAR-T (132)
Cell therapy (386)
Cervical cancer (16)
Clinical research (49846)
Collaboration (779)
Company closure (2)
Compensation (278)
Complete response letters (11)
COVID-19 (2660)
CRISPR (36)
C-suite (223)
Cystic fibrosis (76)
Data (1930)
Decentralized trials (2)
Denatured (25)
Depression (40)
Diabetes (234)
Diagnostics (6541)
Digital health (15)
Diversity (3)
Diversity, equity & inclusion (42)
Drug discovery (102)
Drug pricing (94)
Drug shortages (24)
Duchenne muscular dystrophy (80)
Earnings (73984)
Editorial (44)
Employer branding (20)
Employer resources (132)
Events (86164)
Executive appointments (640)
FDA (15095)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (8)
Funding (633)
Gene editing (84)
Generative AI (25)
Gene therapy (276)
GLP-1 (620)
Government (3986)
Grass and pollen (4)
Guidances (151)
Healthcare (15529)
Huntington's disease (16)
IgA nephropathy (23)
Immunology and inflammation (110)
Indications (27)
Infectious disease (2812)
Inflammatory bowel disease (117)
Inflation Reduction Act (9)
Influenza (55)
Intellectual property (78)
Interviews (397)
IPO (13058)
IRA (38)
Job creations (3084)
Job search strategy (1547)
Kidney cancer (8)
Labor market (33)
Layoffs (409)
Leadership (19)
Legal (6721)
Liver cancer (59)
Lung cancer (270)
Lymphoma (126)
Machine learning (6)
Management (51)
Manufacturing (285)
MASH (65)
Medical device (10694)
Medtech (10698)
Mergers & acquisitions (16169)
Metabolic disorders (585)
Multiple sclerosis (70)
NASH (15)
Neurodegenerative disease (83)
Neuropsychiatric disorders (25)
Neuroscience (1644)
NextGen: Class of 2025 (5266)
Non-profit (3798)
Now hiring (22)
Obesity (300)
Opinion (234)
Ovarian cancer (71)
Pain (69)
Pancreatic cancer (70)
Parkinson's disease (125)
Partnered (19)
Patents (203)
Patient recruitment (90)
Peanut (38)
People (47855)
Pharmaceutical (21)
Pharmacy benefit managers (13)
Phase I (15329)
Phase II (21477)
Phase III (17316)
Pipeline (1281)
Policy (143)
Postmarket research (2179)
Preclinical (6540)
Press Release (70)
Prostate cancer (109)
Psychedelics (25)
Radiopharmaceuticals (234)
Rare diseases (323)
Real estate (4862)
Recruiting (57)
Regulatory (18268)
Reports (33)
Research institute (2005)
Resumes & cover letters (336)
Rett syndrome (6)
RNA editing (4)
RSV (50)
Schizophrenia (66)
Series A (108)
Series B (72)
Service/supplier (6)
Sickle cell disease (46)
Special edition (16)
Spinal muscular atrophy (121)
Sponsored (30)
Startups (2879)
State (1)
Stomach cancer (11)
Supply chain (52)
Tariffs (42)
The Weekly (58)
Vaccines (819)
Venture capitalists (31)
Weight loss (198)
Women's health (25)
Worklife (16)
Date
Today (171)
Last 7 days (846)
Last 30 days (2647)
Last 365 days (26684)
2025 (10029)
2024 (28639)
2023 (32567)
2022 (42847)
2021 (46331)
2020 (45275)
2019 (38438)
2018 (28967)
2017 (27348)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (837)
Alabama (50)
Alaska (6)
Arizona (171)
Arkansas (9)
Asia (32819)
Australia (5708)
California (4992)
Canada (1675)
China (396)
Colorado (235)
Connecticut (259)
Delaware (121)
Europe (78062)
Florida (785)
Georgia (180)
Idaho (40)
Illinois (437)
India (27)
Indiana (263)
Iowa (8)
Japan (159)
Kansas (85)
Kentucky (22)
Louisiana (8)
Maine (68)
Maryland (771)
Massachusetts (3749)
Michigan (222)
Minnesota (303)
Mississippi (2)
Missouri (67)
Montana (25)
Nebraska (21)
Nevada (60)
New Hampshire (52)
New Jersey (1538)
New Mexico (27)
New York (1455)
North Carolina (851)
North Dakota (8)
Northern California (2220)
Ohio (175)
Oklahoma (13)
Oregon (25)
Pennsylvania (1096)
Puerto Rico (3)
Rhode Island (26)
South America (1058)
South Carolina (23)
Southern California (1883)
Tennessee (88)
Texas (760)
United States (19333)
Utah (169)
Virginia (126)
Washington D.C. (56)
Washington State (442)
West Virginia (3)
Wisconsin (56)
574,847 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
April 2, 2025
·
10 min read
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Press Releases
Longhorn Vaccines and Diagnostics Presents Compelling Data on LHNVD-303 Vaccine for Sepsis Related to Bacterial Infections at the World Vaccine Congress
April 25, 2025
·
4 min read
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia Therapy
March 31, 2025
·
2 min read
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic
May 7, 2025
·
2 min read
Vaccines
Is the New HHS Vaccine Requirement Anti-Vaccine Activism Disguised as Policy?
Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for vaccines and sought greater clarity: “I don’t know what they’re talking about.”
May 7, 2025
·
6 min read
·
Heather McKenzie
Press Releases
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
March 20, 2025
·
3 min read
1 of 57,485
Next
